Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Capecitabine + Tetrathiomolybdate |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Capecitabine | Xeloda | R340 | Chemotherapy - Antimetabolite 14 | Xeloda (capecitabine) is an antimetabolite that when activated to 5-FU ultimately inhibits DNA synthesis and cell division (NCI Drug Dictionary). |
| Tetrathiomolybdate | CCRIS 9412|ATN-224 | Tetrathiomolybdate depletes systemic copper, thereby inhibiting cuproenzymes and leading to antitumor effects (PMID: 26160923, PMID: 32005716). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06134375 | Phase Ib/II | Capecitabine Capecitabine + Tetrathiomolybdate Capecitabine + Pembrolizumab + Tetrathiomolybdate Capecitabine + Pembrolizumab | A Study of Tetrathiomolybdate (TM) Plus Capecitabine | Recruiting | USA | 0 |